Merck Appoints Paul J. Diaz to Board of Directors, Expanding Board to 14 Members

Merck & Co., Inc. has appointed Paul J. Diaz to its board of directors, effective November 1, 2026, according to a company press release.

Diaz, managing partner at healthcare-focused private investment firm Cressey & Company, will stand for election by shareholders at the company’s annual meeting in May 2027. His appointment will expand Merck’s board to 14 members.

Diaz brings extensive experience in healthcare services and corporate leadership. Before joining Cressey & Company, he served as president and chief executive officer of Myriad Genetics, Inc., a genetic testing and precision medicine company. Earlier, he was president and CEO of Kindred Healthcare, a Fortune 500 healthcare services company.

In addition to his role at Cressey & Company, Diaz serves on the board of directors of Centene Corporation. He is also a member of the board of trustees of Johns Hopkins Medicine and the board of visitors of Georgetown University Law Center.

Diaz holds a bachelor’s degree in finance and accounting from American University and a law degree from Georgetown University.